Clinical Trial Update: Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating fosaprepitant dimeglumine for prevention of chemotherapy-induced nausea and vomiting; results completed with posted data in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• fosaprepitant dimeglumine (fosaprepitant dimeglumine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 3 | Status: COMPLETED | Results posted: 2015-09-25